Market Movers

The Cooper Companies, Inc.’s Stock Price Skyrockets by 11.84%, Trading at 105.73 USD in a Stellar Performance

The Cooper Companies, Inc. (COO)

105.73 USD +11.19 (+11.84%) Volume: 2.63M

The Cooper Companies, Inc.’s stock price has seen a significant surge, currently trading at 105.73 USD, marking an impressive +11.84% increase this trading session. With a trading volume of 2.63M and a YTD percentage change of +11.75%, COO’s stock performance showcases strong market dynamics.


Latest developments on The Cooper Companies, Inc.

Cooper Cos. has seen a surge in its stock price today following a strong third-quarter performance that surpassed revenue estimates and led to an upgrade in its full-year guidance. The company’s quarterly results beat expectations, prompting analysts to raise their price targets for Cooper Companies (NASDAQ:COO) to $115.00 and $125.00. Wall Street analysts have shown bullish sentiment towards the stock, with Needham & Company LLC giving it a “Hold” rating. Kintegral Advisory LLC also showed confidence in the company by purchasing shares. Overall, Cooper Cos.’s positive earnings and revenue reports have fueled investor optimism and propelled the stock higher.


A look at The Cooper Companies, Inc. Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth3
Resilience2
Momentum4
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

The long-term outlook for Cooper Cos, as indicated by the Smartkarma Smart Scores, shows a mixed picture. While the company scores well in terms of growth and momentum, with scores of 3 and 4 respectively, its value and resilience scores are more moderate at 3 and 2. However, the company’s dividend score is low at 1, indicating that it may not be a strong choice for income-seeking investors.

The Cooper Companies, Inc. is a specialty healthcare products company that develops, manufactures, and markets a range of products including contact lenses and surgical instruments. With a strong focus on growth and momentum, the company is positioned well for future expansion. However, investors should consider the company’s lower scores in terms of value and resilience when evaluating its long-term potential.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars